Immediate high-dose intravenous immunoglobulins followed by direct thrombin-inhibitor treatment is crucial for survival in Sars-Covid-19-adenoviral vector vaccine-induced immune thrombotic thrombocytopenia VITT with cerebral sinus venous and portal vein thrombosis

Graf T, Thiele T, Klingebiel R, Greinacher A, Schäbitz W-R, Greeve I (2021)
Journal of Neurology 268(12): 4483-4485.

Zeitschriftenaufsatz | Veröffentlicht | Englisch
 
Download
OA 673.10 KB
Autor*in
Graf, Tilmann; Thiele, Thomas; Klingebiel, Randolf; Greinacher, Andreas; Schäbitz, Wolf-RüdigerUniBi; Greeve, IsabellUniBi
Erscheinungsjahr
2021
Zeitschriftentitel
Journal of Neurology
Band
268
Ausgabe
12
Seite(n)
4483-4485
ISSN
0340-5354
eISSN
1432-1459
Finanzierungs-Informationen
Open-Access-Publikationskosten wurden durch die Universität Bielefeld im Rahmen des DEAL-Vertrags gefördert.
Page URI
https://pub.uni-bielefeld.de/record/2964825

Zitieren

Graf T, Thiele T, Klingebiel R, Greinacher A, Schäbitz W-R, Greeve I. Immediate high-dose intravenous immunoglobulins followed by direct thrombin-inhibitor treatment is crucial for survival in Sars-Covid-19-adenoviral vector vaccine-induced immune thrombotic thrombocytopenia VITT with cerebral sinus venous and portal vein thrombosis. Journal of Neurology. 2021;268(12):4483-4485.
Graf, T., Thiele, T., Klingebiel, R., Greinacher, A., Schäbitz, W. - R., & Greeve, I. (2021). Immediate high-dose intravenous immunoglobulins followed by direct thrombin-inhibitor treatment is crucial for survival in Sars-Covid-19-adenoviral vector vaccine-induced immune thrombotic thrombocytopenia VITT with cerebral sinus venous and portal vein thrombosis. Journal of Neurology, 268(12), 4483-4485. https://doi.org/10.1007/s00415-021-10599-2
Graf, Tilmann, Thiele, Thomas, Klingebiel, Randolf, Greinacher, Andreas, Schäbitz, Wolf-Rüdiger, and Greeve, Isabell. 2021. “Immediate high-dose intravenous immunoglobulins followed by direct thrombin-inhibitor treatment is crucial for survival in Sars-Covid-19-adenoviral vector vaccine-induced immune thrombotic thrombocytopenia VITT with cerebral sinus venous and portal vein thrombosis”. Journal of Neurology 268 (12): 4483-4485.
Graf, T., Thiele, T., Klingebiel, R., Greinacher, A., Schäbitz, W. - R., and Greeve, I. (2021). Immediate high-dose intravenous immunoglobulins followed by direct thrombin-inhibitor treatment is crucial for survival in Sars-Covid-19-adenoviral vector vaccine-induced immune thrombotic thrombocytopenia VITT with cerebral sinus venous and portal vein thrombosis. Journal of Neurology 268, 4483-4485.
Graf, T., et al., 2021. Immediate high-dose intravenous immunoglobulins followed by direct thrombin-inhibitor treatment is crucial for survival in Sars-Covid-19-adenoviral vector vaccine-induced immune thrombotic thrombocytopenia VITT with cerebral sinus venous and portal vein thrombosis. Journal of Neurology, 268(12), p 4483-4485.
T. Graf, et al., “Immediate high-dose intravenous immunoglobulins followed by direct thrombin-inhibitor treatment is crucial for survival in Sars-Covid-19-adenoviral vector vaccine-induced immune thrombotic thrombocytopenia VITT with cerebral sinus venous and portal vein thrombosis”, Journal of Neurology, vol. 268, 2021, pp. 4483-4485.
Graf, T., Thiele, T., Klingebiel, R., Greinacher, A., Schäbitz, W.-R., Greeve, I.: Immediate high-dose intravenous immunoglobulins followed by direct thrombin-inhibitor treatment is crucial for survival in Sars-Covid-19-adenoviral vector vaccine-induced immune thrombotic thrombocytopenia VITT with cerebral sinus venous and portal vein thrombosis. Journal of Neurology. 268, 4483-4485 (2021).
Graf, Tilmann, Thiele, Thomas, Klingebiel, Randolf, Greinacher, Andreas, Schäbitz, Wolf-Rüdiger, and Greeve, Isabell. “Immediate high-dose intravenous immunoglobulins followed by direct thrombin-inhibitor treatment is crucial for survival in Sars-Covid-19-adenoviral vector vaccine-induced immune thrombotic thrombocytopenia VITT with cerebral sinus venous and portal vein thrombosis”. Journal of Neurology 268.12 (2021): 4483-4485.
Alle Dateien verfügbar unter der/den folgenden Lizenz(en):
Creative Commons Namensnennung 4.0 International Public License (CC-BY 4.0):
Volltext(e)
Access Level
OA Open Access
Zuletzt Hochgeladen
2022-08-02T09:40:25Z
MD5 Prüfsumme
be483ce249da1e4a4fe114de94d5b49e


Zitationen in Europe PMC

Daten bereitgestellt von Europe PubMed Central.

References

Daten bereitgestellt von Europe PubMed Central.

Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®
Quellen

PMID: 34023956
PubMed | Europe PMC

Suchen in

Google Scholar